Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financi...(er share data) ...),Health

Date:11/9/2009

er share data) (Unaudited) Three months ended Six months ended September 30, September 30, 2009 2008 2009 2008 Product sales $17,120 $19,041 $40,404 $31,538 Healthcare services revenue 20,999 19,069 43,047 38,641 Total revenue 38,119 38,110 83,451 70,179 Costs and expenses Product sales costs 12,384 13,187 29,853 23,083 Healthcare services costs 17,352 16,666 34,102 32,401 Selling and marketing expenses 3,608 3,265 6,768 5,724 General and administrative expenses 3,362 3,344 6,040 6,570 Income from operations 1,413 1,648 6,688 2,401 Other (expenses) and income Interest expense (281) (253) (554) (479) Interest income 400 321 872 789 Miscellaneous (expense) income - net 15 (603) (632) (596) Income before income taxes 1,547 1,113 6,374 2,115 Provision for income taxes (1,009) (251) (2,583) (1,415) Net income $538 $862 $3,791 $700 Net income per common share - basic $.04 $.06 $.26 $.05 Weighted average shares outstanding - basic 14,525,528 14,400,655 14,514,453 14,360,758 Net income per common share - diluted $.03 $.05 $.24 $.04 Weighted average shares outstanding - diluted 16,143,679 16,042,327 16,072,536 16,126,008
'/>"/>

SOURCE Chindex International, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Results
2. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
3. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Spherix Reports Second Quarter Earnings
6. Tapestry Reports Second Quarter 2007 Results
7. Callisto Reports on Second-Quarter 2007 Milestones
8. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
9. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
10. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
11. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women